Plasma kallikrein promotes epidermal growth factor receptor transactivation and signaling in vascular smooth muscle through direct activation of protease-activated receptors.
The kallikrein-kinin system, along with the interlocking renin-angiotensin system, is a key regulator of vascular contractility and injury response. The principal effectors of the kallikrein-kinin system are plasma and tissue kallikreins, proteases that cleave high molecular weight kininogen to produce bradykinin. Most of the cellular actions of kallikrein (KK) are thought to be mediated by bradykinin, which acts via G protein-coupled B1 and B2 bradykinin receptors on VSMCs and endothelial cells. Here, we find that primary aortic vascular smooth muscle but not endothelial cells possess the ability to activate plasma prekallikrein. Surprisingly, exposing VSMCs to prekallikrein leads to activation of the ERK1/2 mitogen-activated protein kinase cascade via a mechanism that requires kallikrein activity but does not involve bradykinin receptors. In transfected HEK293 cells, we find that plasma kallikrein directly activates G protein-coupled protease-activated receptors (PARs) 1 and 2, which possess consensus kallikrein cleavage sites, but not PAR4. In vascular smooth muscles, KK stimulates ADAM (a disintegrin and metalloprotease) 17 activity via a PAR1/2 receptor-dependent mechanism, leading sequentially to release of the endogenous ADAM17 substrates, amphiregulin and tumor necrosis factor-α, metalloprotease-dependent transactivation of epidermal growth factor receptors, and metalloprotease and epidermal growth factor receptor-dependent ERK1/2 activation. These results suggest a novel mechanism of bradykinin-independent kallikrein action that may contribute to the regulation of vascular responses in pathophysiologic states, such as diabetes mellitus.
Abdallah
Rany T
RT
Department of Medicine, Medical University of South Carolina, Charleston, South Carolina 29425, USA.
Keum
Joo-Seob
JS
El-Shewy
Hesham M
HM
Lee
Mi-Hye
MH
Wang
Bing
B
Gooz
Monika
M
Luttrell
Deirdre K
DK
Luttrell
Louis M
LM
Jaffa
Ayad A
AA
D051722:ADAM Proteins / Q000235:genetics / Q000378:metabolism; D000072198:ADAM17 Protein; D066258:Amphiregulin; D000818:Animals; D003920:Diabetes Mellitus / Q000235:genetics / Q000378:metabolism; D066255:EGF Family of Proteins; D004789:Enzyme Activation / Q000187:drug effects / Q000502:physiology; D066246:ErbB Receptors / Q000235:genetics / Q000378:metabolism*; D006023:Glycoproteins / Q000235:genetics / Q000378:metabolism; D057809:HEK293 Cells; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000235:genetics / Q000378:metabolism; D007610:Kallikreins / Q000378:metabolism* / Q000494:pharmacology; D020935:MAP Kinase Signaling System / Q000187:drug effects / Q000502:physiology*; D019950:Mitogen-Activated Protein Kinase 1 / Q000235:genetics / Q000378:metabolism*; D048052:Mitogen-Activated Protein Kinase 3 / Q000235:genetics / Q000378:metabolism*; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D044463:Receptor, PAR-1 / Q000235:genetics / Q000378:metabolism*; D044464:Receptor, PAR-2 / Q000235:genetics / Q000378:metabolism*; D018179:Receptors, Thrombin / Q000235:genetics / Q000378:metabolism; D015533:Transcriptional Activation / Q000187:drug effects / Q000502:physiology*
C587848:AREG protein, human; D066258:Amphiregulin; C587850:Areg protein, rat; D066255:EGF Family of Proteins; D006023:Glycoproteins; D036341:Intercellular Signaling Peptides and Proteins; D044463:Receptor, PAR-1; D044464:Receptor, PAR-2; D018179:Receptors, Thrombin; C512478:EGFR protein, human; C483803:Egfr protein, rat; D066246:ErbB Receptors; C535150:MAPK1 protein, human; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D007610:Kallikreins; D051722:ADAM Proteins; D000072198:ADAM17 Protein; C000606462:ADAM17 protein, human; C000606464:Adam17 protein, rat; C112908:protease-activated receptor 4
J Clin Invest. 1989 May;83(5):1774-7
2540223
Circ Res. 1994 Dec;75(6):1029-38
7955141
J Biol Chem. 2002 Apr 12;277(15):12838-45
11823465
Biol Chem. 2008 Jun;389(6):643-51
18627296
Circulation. 1996 Dec 1;94(11):2778-86
8941102
J Invest Dermatol. 2008 Jan;128(1):18-25
17625593
Thromb Haemost. 2008 Feb;99(2):305-15
18278179
J Pharmacol Exp Ther. 2002 Feb;300(2):702-8
11805236
J Atheroscler Thromb. 2005;12(2):73-6
15942116
J Biol Chem. 1992 Mar 25;267(9):6081-5
1313429
Pharmacol Rev. 2001 Jun;53(2):245-82
11356985
J Clin Pathol. 2004 May;57(5):513-6
15113859
Arterioscler Thromb Vasc Biol. 1996 Dec;16(12):1524-31
8977458
Exp Cell Res. 2003 Mar 10;284(1):2-13
12648462
J Thromb Haemost. 2005 Aug;3(8):1800-14
16102047
J Cardiovasc Pharmacol. 1997 Nov;30(5):649-57
9388048
J Cardiovasc Pharmacol. 1993 Oct;22(4):609-16
7505364
Am J Physiol. 1994 Nov;267(5 Pt 2):H1962-7
7526715
Circ Res. 2003 Aug 22;93(4):302-10
12869389
Annu Rev Pharmacol Toxicol. 1995;35:679-705
7598512
J Biol Chem. 2006 Feb 10;281(6):3116-26
16321973
J Clin Invest. 1992 Oct;90(4):1614-21
1328304
Sci STKE. 2000 Jan 18;2000(15):pe1
11865189
Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
11252954
Am J Physiol. 1989 Jul;257(1 Pt 2):F60-6
2546445
Am J Physiol Heart Circ Physiol. 2004 Mar;286(3):H926-32
14766673
Br J Pharmacol. 2000 Jul;130(5):1140-6
10882400
Biochem Biophys Res Commun. 1993 Nov 30;197(1):256-62
8250932
Int Immunopharmacol. 2008 Feb;8(2):161-5
18182220
Trends Endocrinol Metab. 2004 Aug;15(6):286-93
15358282
Br J Pharmacol. 2000 Dec;131(8):1635-42
11139441
J Biol Chem. 2006 Oct 27;281(43):32095-112
16885167
J Cell Biol. 2004 Mar 1;164(5):769-79
14993236
Biochem Biophys Res Commun. 2003 Feb 21;301(4):1109-15
12589827
J Cell Sci. 1999 Nov;112 ( Pt 21):3603-17
10523497
J Clin Invest. 1993 Jan;91(1):94-8
8380817
Arterioscler Thromb Vasc Biol. 2006 Sep;26(9):e133-7
16840716
Thromb Haemost. 2001 Sep;86(3):840-7
11583317
J Vasc Surg. 2003 Mar;37(3):644-9
12618705
Thromb Haemost. 1995 Nov;74(5):1340-7
8607120
Lab Invest. 2005 Jan;85(1):9-23
15568038
Am J Physiol. 1993 Feb;264(2 Pt 2):F322-7
8447442
Trends Pharmacol Sci. 1999 Oct;20(10):408-12
10577253
Br J Pharmacol. 2008 Mar;153 Suppl 1:S263-82
18059329
J Mol Endocrinol. 2003 Apr;30(2):117-26
12683936
J Clin Invest. 2002 Apr;109(8):1007-9
11956236
Circulation. 1996 Jul 1;94(1):44-51
8964116
J Biol Chem. 1994 Mar 4;269(9):6399-404
8119989
Blood Coagul Fibrinolysis. 1995 Dec;6(8):753-60
8825227
Thromb Haemost. 1999 May;81(5):808-14
10365757
Immunopharmacology. 1999 Dec;45(1-3):135-9
10615002
Eur J Pharmacol. 1998 Jun 12;351(1):67-77
9698207
Mol Cell Proteomics. 2005 May;4(5):626-36
15705970
Atherosclerosis. 2006 Jul;187(1):82-91
16214147
Atherosclerosis. 2006 May;186(1):38-53
16076471
Hypertension. 1997 Mar;29(3):757-62
9052892
J Biol Chem. 2008 May 2;283(18):12293-304
18308730
Thromb Haemost. 2007 Jul;98(1):77-83
17597995
Ann N Y Acad Sci. 2001 Dec;947:42-54; discussion 54-5
11795306
Physiol Rev. 2004 Apr;84(2):579-621
15044683
J Neurochem. 2008 Nov;107(3):855-70
18778305
Arterioscler Thromb Vasc Biol. 2007 Jan;27(1):27-36
17095716
Arterioscler Thromb Vasc Biol. 2006 Apr;26(4):685-8
16556862
Blood. 1998 Jan 15;91(2):516-28
9427705
Diabetes. 2003 May;52(5):1215-21
12716755
Am J Physiol Regul Integr Comp Physiol. 2003 Jul;285(1):R1-13
12793984